nilotinib + ruxolitinib

The combination of **nilotinib** (a BCR-ABL tyrosine kinase inhibitor) and **ruxolitinib** (a Janus kinase 1/2 inhibitor) is under investigation primarily as a therapy for myelofibrosis (MF) and chronic phase chronic myeloid leukemia (CP-CML). The rationale for this combination is based on synergistic activity, with ruxolitinib providing immunomodulatory and anti-proliferative effects via inhibition of the JAK-STAT pathway, and nilotinib contributing antifibrotic effects through inhibition of PDGF receptor signaling and blockade of BCR-ABL[1][3][5]. Dual inhibition of JAK/STAT (notably STAT5) and MAPK (ERK) signaling has been demonstrated, resulting in enhanced suppression of pathological hematopoietic clones, reduction of fibrosis, and decreased synthesis of pro-inflammatory cytokines and collagen[1][4]. Early-phase clinical trials have indicated the regimen is safe and produces encouraging molecular responses[5].

Other names

nilotinib + ruxolitinib